These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19762784)

  • 1. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia.
    Cariou B; Ouguerram K; Zaïr Y; Guerois R; Langhi C; Kourimate S; Benoit I; Le May C; Gayet C; Belabbas K; Dufernez F; Chétiveaux M; Tarugi P; Krempf M; Benlian P; Costet P
    Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2191-7. PubMed ID: 19762784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.
    Si-Tayeb K; Idriss S; Champon B; Caillaud A; Pichelin M; Arnaud L; Lemarchand P; Le May C; Zibara K; Cariou B
    Dis Model Mech; 2016 Jan; 9(1):81-90. PubMed ID: 26586530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.
    Ouguerram K; Chetiveaux M; Zair Y; Costet P; Abifadel M; Varret M; Boileau C; Magot T; Krempf M
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1448-53. PubMed ID: 15166014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
    Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
    Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
    Lin J; Wang LY; Liu S; Wang XM; Yong Q; Yang Y; DU LP; Pan XD; Wang X; Jiang ZS
    Chin Med J (Engl); 2010 May; 123(9):1133-8. PubMed ID: 20529551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol.
    Fasano T; Cefalù AB; Di Leo E; Noto D; Pollaccia D; Bocchi L; Valenti V; Bonardi R; Guardamagna O; Averna M; Tarugi P
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):677-81. PubMed ID: 17170371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypobetalipoproteinemia and abetalipoproteinemia.
    Welty FK
    Curr Opin Lipidol; 2014 Jun; 25(3):161-8. PubMed ID: 24751931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.
    Zhao Z; Tuakli-Wosornu Y; Lagace TA; Kinch L; Grishin NV; Horton JD; Cohen JC; Hobbs HH
    Am J Hum Genet; 2006 Sep; 79(3):514-23. PubMed ID: 16909389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population.
    Yue P; Averna M; Lin X; Schonfeld G
    Hum Mutat; 2006 May; 27(5):460-6. PubMed ID: 16619215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins.
    Fazio S; Minnier J; Shapiro MD; Tsimikas S; Tarugi P; Averna MR; Arca M; Tavori H
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3340-3348. PubMed ID: 28633452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial hypobetalipoproteinemia caused by homozygous loss-of-function mutations in PCSK9: A case report.
    Kudo T; Sasaki K; Tada H
    J Clin Lipidol; 2022; 16(5):596-600. PubMed ID: 35931648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial hypobetalipoproteinemia in a hospital survey: genetics, metabolism and non-alcoholic fatty liver disease.
    Gutiérrez-Cirlos C; Ordóñez-Sánchez ML; Tusié-Luna MT; Patterson BW; Schonfeld G; Aguilar-Salinas CA
    Ann Hepatol; 2011; 10(2):155-64. PubMed ID: 21502677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Healthy Family of Familial Hypobetalipoproteinemia Caused by a Protein-truncating Variant in the PCSK9 Gene.
    Tada H; Okada H; Nomura A; Nohara A; Takamura M; Kawashiri MA
    Intern Med; 2020; 59(6):783-787. PubMed ID: 32173689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture.
    Mayne J; Dewpura T; Raymond A; Bernier L; Cousins M; Ooi TC; Davignon J; Seidah NG; Mbikay M; Chrétien M
    Clin Chem; 2011 Oct; 57(10):1415-23. PubMed ID: 21813713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
    Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
    Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel APOB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia.
    Rimbert A; Pichelin M; Lecointe S; Marrec M; Le Scouarnec S; Barrak E; Croyal M; Krempf M; Le Marec H; Redon R; Schott JJ; Magré J; Cariou B
    Atherosclerosis; 2016 Jul; 250():52-6. PubMed ID: 27179706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma PCSK9 levels correlate with cholesterol in men but not in women.
    Mayne J; Raymond A; Chaplin A; Cousins M; Kaefer N; Gyamera-Acheampong C; Seidah NG; Mbikay M; Chrétien M; Ooi TC
    Biochem Biophys Res Commun; 2007 Sep; 361(2):451-6. PubMed ID: 17645871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia.
    Hooper AJ; Heeks L; Robertson K; Champain D; Hua J; Song S; Parhofer KG; Barrett PH; van Bockxmeer FM; Burnett JR
    J Clin Endocrinol Metab; 2015 Nov; 100(11):E1484-90. PubMed ID: 26323024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.
    Vergès B; Duvillard L; Brindisi MC; Gautier E; Krempf M; Costet P; Cariou B
    Atherosclerosis; 2011 Nov; 219(1):342-8. PubMed ID: 21889145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.